A multi-center, parallel-group comparison, double-blind, placebo-controlled, randomized, trial to determine the safety, pharmacokinetics, and efficacy of OPC-108459 administered as a single intravenous dose to subjects with paroxysmal or persistent atrial fibrillation (Phase 1 trial)
Latest Information Update: 16 Feb 2017
At a glance
- Drugs OPC 108459 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 03 Jun 2016 New trial record